(Reuters) - A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks. from Reuters: Health News http://ift.tt/2HXlsQy
Post a Comment